The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease

Thumbnail

View/Open

Access

info:eu-repo/semantics/openAccess

Date

2023

Author

Yılmaz, Yusuf
Kaya, Eda

Metadata

Show full item record

Citation

Yilmaz, Y., & Kaya, E. (2023). The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum, 4(2), I–II. https://doi.org/10.14744/hf.2022.2022.0044

Abstract

Among chronic liver conditions, metabolic (dysfunction)-associated fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and growing.

Source

Hepatology Forum

Volume

4

Issue

2

URI

https://doi.org/10.14744/hf.2022.2022.0044
https://hdl.handle.net/11436/8087

Collections